Fruitful discussions, one goal: Together we want to pool the know-how in our core competences, officially announced by Motic, the young manufacturer of Whole Slide Scanners and Xyall as a MedTech innovator in molecular pathology. The aim is to develop a compact, automated workstation for the handling and analysis of tumors in molecular pathology laboratories.
This strategical partnership with focus on the development of future systems combines the Xyall-P-Platform with functions of digital pathology from Motic. Both companies expect the first table-top product for the autumn of next year.
Xyall is well-known on the market. Since 2019, Xyall is working with the high-tech engineering company Sioux to add high-precision medical robot solutions and machine-learning components to their platforms. Now the new aim is defined with Motic as new partner.
Motic based on a decade-long experience in the manufacturing of high-quality light microscopes and affordable digital imaging systems, entered successfully into the field of pathology years ago.
A series of Whole-Slide-Scanners from the MoticEasyScan Line found a worldwide distribution. MOTIC FLOW as a cloud-computing platform for a second opinion in digital pathology accelerated the medical cooperation between experts from different countries.
As the leading digital pathology solution provider operating the largest tele-pathology consultation platform and five independent clinical Laboratories (ICL) in China, Motic’s strategic partnership with Xyall is a consequent step to improve the pathological workflow for a better medical care of patients.
The tissue section nowadays is a labor-intensive process with a risk of error and cross-contamination. It is evident that only a complete solution will open this bottleneck in pathology workflow and eliminates human errors. The cooperation will create a platform for lab technicians as well as laboratory managers to ensure faster and more efficient sampling for more accurate diagnosis. An automated system will also support the existing decision-making levels in the lab.
In addition to the solutions for the hospital, Xyall and Motic intend to develop and launch an industrial solution for the high throughput demand of huge commercial pathology laboratories. With the same technology platform, the launch of this large-scale system is planned for spring 2021.
"We are happy to join forces with Motic," says Guido du Pree. "The knowledge and experience in optics, imaging, pathology workflow as well as the strong market position in digital pathology especially in Asia are an enormous impact and will drive our development and commercialization. The combined experience of our strategic partners creates a dynamic, over-the-top alliance to create and advance our unique global approach to satisfy both the high-volume sample throughput and the pathology of each single hospital."
Richard Yeung, CEO of Motic, adds: "Motic is not only an established global provider of microscopy and digital pathology solutions, but also operates one of the largest telepathology consulting platforms in the world. Together with Xyall and Sioux, we are confident that we can leverage our synergies to create another milestone in digital pathology industry."
The current practice of tissue testing involves the pathologist in the hand-marked ROIs (Regions of Interest) on hematoxylin/eosin-dyed samples. With the help of this visual assessment, laboratory technicians translate these ROIs into cutting planes, remove the tissue manually and position it into small containers. In view of the worldwide shortage of laboratory technicians, our future system relieves the time-pressure burden on clinical laboratories.